Table 1. Clinical characteristics and selected outcomes of patients within cohort (n = 195) and subset of patients who had CT scans done (n = 75).
| Characteristics | Cohort (n = 195) | Patients with CT scans (n = 75) |
|---|---|---|
| Age, average (std dev), range, yr | 55.5 (15.4), 20–92 | 54 (13.4), 20–88 |
| Male Sex, n (%) | 133 (68%) | 52 (69%) |
| Ethnicity (% Hispanic) | 126 (65%) | 45 (60%) |
| Race | ||
| • Native American | 5 (2.5%) | 3 (4%) |
| • Pacific Islander | 4 (2%) | 3 (4%) |
| • Asian | 29 (9.8%) | 9 (12%) |
| • Black | 29 (9.8%) | 10 (13%) |
| • White | 115 (59%) | 44 (59%) |
| • Multiracial | 2 (1%) | 2 (2.6%) |
| • Unknown | 11 (5.6%) | 4 (5%) |
| BMI, average, kg/m2 | 31.8 | 32.5 |
| OSH Transfer, n (%) | 101 (52%) | 46 (61%) |
| ARDS at enrollment, n (%) | 74 (38%) | 38 (51%) |
| NIV/HFNC at enrollment, n (%) | 55 (28%) | 21 (28%) |
| Mechanical ventilation at enrollment, n (%) | 100 (51%) | 50 (67%) |
| ECLS at enrollment, n (%) | 16 (8%) | 9 (12%) |
| Received dexamethasone | 147 (75%) | 64 (85%) |
| Received any dose of COVID vaccination, n (%) | 7 (3.5%) | 4 (5%) |
| Admission P:F, median (IQR) | 60 (40–90) | 60 (50–90) |
| APACHE, median (IQR) | 70.5 (52–93.3) | 76 (54–95) |
| RALE score, day 1, median (IQR) | 22 (12–28) | 24 (14–32) |
| COVID test to proximal sample date, median (IQR), days | 4 (1–11) | 7 (1–14) |
| Outcomes | ||
| In-hospital death, n (%) | 83 (43%) | 24 (32%) |
| VFDs <14, n (%) | 118 (60%) | 45 (60%) |
| Treatment for refractory hypoxemia, n (%) | 101 (52%) | 41 (55%) |
BMI–body measurement index, OSH = outside hospital, ARDS–acute respiratory distress syndrome, NIV- non-invasive mechanical ventilation, HFNC–high flow nasal cannula, ECLS- extracorporeal life support, COVID- coronavirus disease 2019, P:F–Ratio of the PaO2 to the delivered FiO2, APACHE–Acute Physiology, Age, Chronic Health Evaluation III, RALE–Radiographic Assessment of Lung Edema